Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
Public ClinicalTrials.gov record NCT00240617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (*Treximet)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Study identification
- NCT ID
- NCT00240617
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 623 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2005 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Jun 2006 (Actual)
- Last update posted
- Oct 26, 2016
2005 – 2006
United States locations
- U.S. sites
- 52
- U.S. states
- 27
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Tuscaloosa | Alabama | 35406 | — |
| GSK Investigational Site | Mesa | Arizona | 85201 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Hot Springs | Arkansas | 71913 | — |
| GSK Investigational Site | Irvine | California | 92618 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | San Diego | California | 92108 | — |
| GSK Investigational Site | San Diego | California | 92128 | — |
| GSK Investigational Site | Boulder | Colorado | 80304 | — |
| GSK Investigational Site | Avon | Connecticut | 06001 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | South Daytona | Florida | 32119 | — |
| GSK Investigational Site | Stuart | Florida | 34996 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Decatur | Georgia | 30033 | — |
| GSK Investigational Site | Rome | Georgia | 30165 | — |
| GSK Investigational Site | Chicago | Illinois | 60607 | — |
| GSK Investigational Site | Evansville | Indiana | 47712 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48104 | — |
| GSK Investigational Site | Saint Louis Park | Minnesota | 55426 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Moorestown | New Jersey | 08057 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87108 | — |
| GSK Investigational Site | Albany | New York | 12206 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | Plainview | New York | 11803 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Valley Stream | New York | 11580 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Greensboro | North Carolina | 27401 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Concinnati | Ohio | 45219 | — |
| GSK Investigational Site | West Chester | Ohio | 45069 | — |
| GSK Investigational Site | Westerville | Ohio | 43081 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| GSK Investigational Site | Eugene | Oregon | 97401 | — |
| GSK Investigational Site | Salem | Oregon | 97301 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19114 | — |
| GSK Investigational Site | Anderson | South Carolina | 29621 | — |
| GSK Investigational Site | Bristol | Tennessee | 37620 | — |
| GSK Investigational Site | Clarksville | Tennessee | 37043 | — |
| GSK Investigational Site | Memphis | Tennessee | 38105 | — |
| GSK Investigational Site | Fort Worth | Texas | 76135 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84121 | — |
| GSK Investigational Site | Seattle | Washington | 98195 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00240617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2016 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00240617 live on ClinicalTrials.gov.